Options
Taiwan Nationwide Study of First-Line ALKāTKI Therapy in ALK-Positive Lung Adenocarcinoma
Journal
Targeted Oncology
Date Issued
2024-11-01
Author(s)
Abstract
Background: The clinical outcomes of patients with anaplastic lymphoma kinase-positive (ALK+) advanced lung adenocarcinoma vary according to real-world data. Objective: In this study, we aimed to investigate the treatment discontinuation (TTD) and overall survival (OS) of patients with ALK+ advanced lung adenocarcinoma treated with first-line ALKāTKIs in Taiwan. Patients and Methods: This retrospective study evaluated all advanced lung adenocarcinoma patients registered in the National Taiwan Cancer Registry from 2017 to 2020 who had ALK rearrangement and received ALKāTKI treatment, using data from Taiwanās National Health Insurance Research Database (NHIRD). The TKI treatment sequences were classified into first generation (G1: crizotinib), second generation (G2: ceritinib, alectinib, brigatinib), and third generation (G3: lorlatinib). Results: A total of 587 patients were analyzed, with a median age of 60.0 years, 91 (15.5%) aged ā„ 74 years, 293 (49.9%) female, 397 (67.6%) never smoked, and 534 (91.0%) with stage IV disease. Patients who received next-generation ALKāTKIs during the treatment course had longer median time to ALKāTKI TTD and OS. The TTD of the G1, G1+2, G1+2+3, G2, and G2+3 groups was 7.5 (5.4ā11.1), 40.6 (29.4ānot calculated (NC)), 50.3 (41.3āNC), 34.3 (29.2ā43.0), and 36.3 (22.4āNC) months, respectively (p < 0.001). The median OS of the patients in the G1, G1+2, G1+2+3, G2, and G2+3 groups was 10.6 (7.5ā14.6), not reached (NR) (NCāNC), NR (NCāNC), 43.0 (36.3āNC), and NR (30.3āNC) months, respectively (p < 0.001). Compared with treatment with crizotinib alone, the multivariate analysis revealed that treatment with next-generation TKIs was independently associated with longer TTD (G1+2 (hazard ratio (HR), 0.24; 95% CI 0.17ā0.33; p < 0.001), G1+2+3 or G1+3 (HR, 0.17; 95% confidence interval (CI), 0.10ā0.28; p < 0.001), G2 (HR, 0.26; 95% CI 0.19ā0.36; p < 0.001), and G2+3 (HR, 0.25; 95% CI 0.14ā0.44; p < 0.001)) and median OS (G12 (HR, 0.24; 95% CI 0.17ā0.35; p < 0.001), G1+2+3 or G1+3 (HR, 0.09; 95% CI 0.04ā0.21; p < 0.001), G2 (HR, 0.22; 95% CI 0.15ā0.31; p < 0.001), and G2+3 (HR, 0.20; 95% CI 0.10ā0.42; p < 0.001)). Conclusions: For patients with ALK+ NSCLC, treatments including next-generation ALKāTKIs were independently associated with longer survival outcomes.
Type
journal article